Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 3 1Phase 2/3 1Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1NET 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 75Lung Neoplasms 48Small Cell Lung Carcinoma 11Neoplasms 10NSCLC 8Colorectal Neoplasms 7Prostatic Neoplasms 6Ovarian Neoplasms 6Brain Neoplasms 6Mesothelioma 5Breast Neoplasms 5Pancreatic Neoplasms 4Neoplasm Metastasis 4Melanoma 4Head and Neck Neoplasms 4Adenocarcinoma of Lung 4Liver Neoplasms 3Hematologic Neoplasms 3Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Sarcoma 2Recurrence 2Neoplasms by Site 2Neoplasms by Histologic Type 2Multiple Myeloma 2Laryngeal Neoplasms 2

Interventions

Oxaliplatin 1Leucovorin 1Fluorouracil 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Carcinoma, Islet Cell × Thoracic × Clear all
NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡